Beijing Luzhu Biotechnology Co., Ltd.
Research Beijing Luzhu Biotechnology Co., Ltd. (2480.HK) on Bullrun: market cap HKD 3.04B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker2480.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyHKD
- Market capHKD 3.04B
- Financial periodFY2025
- RevenueCNY 0
- Net income-CNY 150.36M
- Free cash flow-CNY 190.39M
Valuation Snapshot
latest market cap is HKD 3.04B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 0 | -CNY 150.36M | -CNY 190.39M | n/a | -0.75 | CNY 95.95M | CNY 273.00M | CNY 660.12M |
| FY2024 | CNY 0 | -CNY 168.24M | -CNY 184.47M | n/a | -0.83 | CNY 140.13M | CNY 67.53M | CNY 853.59M |
| FY2023 | CNY 0 | -CNY 249.35M | -CNY 277.07M | n/a | -1.25 | CNY 264.98M | CNY 19.22M | CNY 1.02B |
| FY2022 | CNY 0 | -CNY 725.18M | -CNY 334.36M | n/a | -3.58 | CNY 68.98M | CNY 11.22M | CNY 937.47M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 3.04B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About Beijing Luzhu Biotechnology Co., Ltd.
Beijing Luzhu Biotechnology Co., Ltd., a biotechnology company, develops human vaccines and therapeutic biologics to prevent and control infectious diseases, and to treat cancer and autoimmune diseases in Mainland China. The company is developing LZ901, a recombinant herpes zoster vaccine for which a biologics license application (BLA) has been submitted;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Beijing Luzhu Biotechnology Co., Ltd.'s market cap?
Beijing Luzhu Biotechnology Co., Ltd.'s market capitalization is HKD 3.04B.
What does Beijing Luzhu Biotechnology Co., Ltd. do?
Beijing Luzhu Biotechnology Co., Ltd., a biotechnology company, develops human vaccines and therapeutic biologics to prevent and control infectious diseases, and to treat cancer and autoimmune diseases in Mainland China.